Arcus Biosciences (RCUS) Interest Coverage Ratio (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Interest Coverage Ratio of 44.67 for Q1 2026, up 26.78% year-over-year from 35.23 in Q1 2025, and up 60.82% quarter-over-quarter from 114.0 in Q4 2025.
Arcus Biosciences (RCUS) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Arcus Biosciences' Interest Coverage Ratio history runs 10 years deep, the most recent figure standing at 44.67 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 26.78% year-over-year to 44.67; the TTM figure through Mar 2026 stood at 44.22 (up 69.57% YoY), while the FY2025 annual figure was 0.94, up 10.29% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 44.67, up from 114.0 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 103.0 in Q4 2024, with the low at 114.0 in Q4 2025.
- The 5-year median for Interest Coverage Ratio is 20.75 (2023), against an average of 26.59.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio jumped 530.41% in 2023, then tumbled 410.84% in 2024.
- Arcus Biosciences' Interest Coverage Ratio stood at 10.57 in 2022, then surged by 530.41% to 45.5 in 2023, then soared by 126.37% to 103.0 in 2024, then slumped by 210.68% to 114.0 in 2025, then surged by 60.82% to 44.67 in 2026.
- Business Quant data shows RCUS's Interest Coverage Ratio at 44.67 in Q1 2026, 114.0 in Q4 2025, and 35.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -32.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.00 |
| Mar 31, 2026 | -44.67 |
| Dec 31, 2025 | -114.00 |
| Sep 30, 2025 | -35.50 |
| Jun 30, 2025 | -8.00 |
| Mar 31, 2025 | -61.00 |
| Dec 31, 2024 | 103.00 |
| Sep 30, 2024 | -105.00 |
| Jun 30, 2024 | -106.00 |
| Mar 31, 2024 | -16.00 |
| Dec 31, 2023 | 45.50 |
| Sep 30, 2023 | -26.67 |
| Jun 30, 2023 | -20.75 |
| Mar 31, 2023 | -21.50 |
| Dec 31, 2022 | -10.57 |
| Sep 30, 2022 | -7.12 |
| Jun 30, 2022 | -9.51 |
| Mar 31, 2022 | -14.25 |
| Dec 31, 2021 | 70.25 |
| Sep 30, 2021 | -4.91 |